Health Care Supplies

CIRC

Circle

Conference Minutes

CRCL

HSBA

00005

DEFI

HSBC

01763

CVAC

APO-A

HSHD

The following are the Minutes of the $Circle (CRCL.US) FY25 Q3 earnings call. For a quick interpretation, you can simply review the Quick Interpretation of the financial report. 1. Financial Core Data Review: (1) Performance Overview: USDC circulation reached $73.7 billion, a year-on-year increase of 108%; on-chain transaction volume was $9.6 trillion, a year-on-year increase of 580%. (2) Profitability: Total revenue and reserve earnings were $740 million, a year-on-year increase of 66%; Adjusted EBITDA was $166 million, a year-on-year increase of 78%. The profit margin reached 57%...

Deutsche Boerse AG

HSBC Holdings Plc

HSBC HOLDINGS

Hashdex Bitcoin Futures ETF

Apollo Global

BlackRock

Ameriprise Financial

SentinelOne

Citigroup

CureVac BV

APOLLO GLOBAL MANAGEMENT INC 6.75% CONV PFD STK SER A

HSBC HK SDR 5to1

Circle (Minutes): The Ecological Network is More Important than Commercialization

Scattered Neutron Source Achieves Production of Medical Alpha Isotopes and Signs Comprehensive Industry Agreement

CIRC released FY2025 9 Months Earnings on March 27 (BJT), actual revenue HKD 5.461 B, actual EPS HKD 0.8477

CIRC released FY2025 Q3 earnings on March 27, 2026 (BJT), with actual revenue of HKD 2.367 B and EPS of HKD 0.2655

CIRC released FY2025 Annual Earnings on March 27 After-Market BJT, actual revenue HKD 7.856 B, actual EPS HKD 1.1148

CIRC released FY2025 Q4 earnings on March 27 After-Market (BJT), actual revenue HKD 2.407 B, actual EPS HKD 0.2701

CIRC FY2025 Annual Earnings Release on March 27, 2026 After-Market (BJT)

China Nuclear Hi-Tech's Boron [10B] Phenylalanine Enters Phase I Clinical Trials

China National Nuclear Corporation's Affiliated Company CNHH BioTech's Drug Clinical Trial Application Approved

China Tongfu's subsidiary Atom High-Tech signs commercial agreement with Novartis for Pivowart

Atomic High-tech Co., Ltd. Participates in Winning the First Prize for Childhood Neuroblastoma Research Project

China National Isotope Corporation's Atomic High-tech Signs Agreement on Fluorine [18F] Bezafibrate Project with Beijing Normal University

CIRC Signs Strategic Cooperation Agreement with CNNC Capital

China Radiopharmaceutical Signs Gamma Irradiation Station Contract with Peru

CIRC Makes First Export of Cobalt-60 Radioisotopes to Brazil

UBS Increases Stake in China National Isotope to 5.01%

China National Nuclear Corporation's subsidiary wins a champion title in the pharmaceutical industry

China National Nuclear Corporation's Tongfu Announces Release of Carbon Isotopes and Launch of Phase II Project

China National Isotope Corporation Successfully Develops Isotope Separation Technology and Signs International Cooperation Memorandum

China National Nuclear Corporation signs isotope procurement MOU with Brazilian nuclear agency

China Isotope Holdings' Boron [10B] Phenylalanine Injection Receives CDE Acceptance

CH DEMETER FIN

FAMEGLOW

LUEN THAI

NEW GONOW RV

REF HOLDINGS

PARADISE ENT

WEBX HOLDING

HAICHANG HLDG

BEST FOOD HLDG

INTELLIMARK W27

China National Nuclear Corporation Co., Ltd. 2025 Annual Performance Conference

CIRC announced its 2025 annual performance, with operating revenue of RMB 7.188 billion, a year-on-year decrease of 5.1%. It recorded a net profit of RMB 327 million, a decline of 19.5%, with earnings per share of RMB 1.02. A final dividend of 22.64 cents was declared

AASTOCKS

"Performance" CIRC's annual net profit is 327 million RMB, a decrease of 19.5%, with a final dividend of 22.64 cents

601985

CIRC Strikes Strategic Nuclear Technology Pact With Maoming City Government

Tip Ranks

CNNP

CIRC Strikes Strategic Nuclear Technology Pact With Maoming City Government

The clinical trial application for the improved new drug "Injection Boron [10B] Falan" developed by China CIRC's subsidiary China Nuclear Huadewei has been approved by the National Medical Products Administration. This drug has significant clinical advantages for head and neck tumors, with a short treatment course and low toxicity

CIRC's subsidiary's application for clinical trials of improved new drugs has been approved

China Isotope & Radiation Corporation (CIRC) announced that its subsidiary, Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd., has received the National-Level Manufacturing Enterprise recognition and the ‘Single-Item Champion in the Pharmaceutical Industry’ award for its Urea [13C/14C] Breath Test Kits. This achievement highlights CIRC's leadership in breath diagnostics and commitment to innovation. The current analyst rating for CIRC's stock (HK:1763) is a Buy, with a price target of HK$21.00, and the company has a market cap of HK$6.19B.

CIRC’s Breath Diagnostic Product Wins National-Level Champion Award

CIRC rose more than 7% during the session, and as of the time of writing, it is up 5.11%, trading at HKD 20.16, with a transaction volume of HKD 10.3578 million. On the news front, on October 31, the launch conference for the carbon isotope product release and the construction of the second phase of the stable isotope base project was successfully held in Tongcheng, Anhui. The high-abundance 13CO gas and urea products were officially released, marking a breakthrough for China in reducing its long-term reliance on imported 13CO gas for urea breath diagnostic materials. China has achieved comprehensive self-control of the entire industrial chain from key raw materials to end products in the field of medical stable isotope carbon, making the company a leading enterprise that fully masters the entire industrial chain of breath test products. According to public information, CIRC is a specialized company in the nuclear technology application sector of China National Nuclear Corporation, integrating nuclear energy development, production, sales, and services. Its main business includes nuclear medicine, radiation source products, nuclear medical equipment, and related technical services. The company has a complete industrial chain layout in the field of nuclear medicine, and as of December 31, 2024, it has established a network layout of 37 medical centers and has 7 R&D and production bases, making it a leading enterprise in China's nuclear medicine field

Zhitong

Understanding the Market | CIRC rose over 7% during trading as the company launched high-purity 13CO gas and urea products to support the comprehensive autonomy and controllability of the industrial chain

CIRC(01763.HK)

"Performance" CIRC's annual net profit is 327 million RMB, a decrease of 19.5%, with a final dividend of 22.64 cents

CIRC Strikes Strategic Nuclear Technology Pact With Maoming City Government

CIRC's subsidiary's application for clinical trials of improved new drugs has been approved

Circle (Minutes): The Ecological Network is More Important than Commercialization

CIRC’s Breath Diagnostic Product Wins National-Level Champion Award

Understanding the Market | CIRC rose over 7% during trading as the company launched high-purity 13CO gas and urea products to support the comprehensive autonomy and controllability of the industrial chain